NASDAQ:OSMT

Osmotica Pharmaceuticals Competitors

$3.05
-0.11 (-3.48 %)
(As of 04/20/2021 11:57 AM ET)
Add
Compare
Today's Range
$3.02
Now: $3.05
$3.12
50-Day Range
$2.97
MA: $3.53
$4.00
52-Week Range
$2.95
Now: $3.05
$9.67
Volume1,945 shs
Average Volume377,967 shs
Market Capitalization$190.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2.92

Competitors

Osmotica Pharmaceuticals (NASDAQ:OSMT) Vs. EPZM, ORIC, ESPR, HGEN, XENE, and LXRX

Should you be buying OSMT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Osmotica Pharmaceuticals, including Epizyme (EPZM), ORIC Pharmaceuticals (ORIC), Esperion Therapeutics (ESPR), Humanigen (HGEN), Xenon Pharmaceuticals (XENE), and Lexicon Pharmaceuticals (LXRX).

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares Osmotica Pharmaceuticals and Epizyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Osmotica Pharmaceuticals-25.26%-13.23%-3.91%
Epizyme-1,899.35%-83.45%-52.66%

Volatility & Risk

Osmotica Pharmaceuticals has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Osmotica Pharmaceuticals and Epizyme, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Osmotica Pharmaceuticals01302.75
Epizyme04302.43

Osmotica Pharmaceuticals presently has a consensus price target of $9.25, indicating a potential upside of 203.28%. Epizyme has a consensus price target of $16.5714, indicating a potential upside of 117.47%. Given Osmotica Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Osmotica Pharmaceuticals is more favorable than Epizyme.

Valuation & Earnings

This table compares Osmotica Pharmaceuticals and Epizyme's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Osmotica Pharmaceuticals$240.03 million0.80$-270,900,000.00$0.2512.20
Epizyme$23.80 million33.06$-170,290,000.00($1.93)-4.01

Epizyme has lower revenue, but higher earnings than Osmotica Pharmaceuticals. Epizyme is trading at a lower price-to-earnings ratio than Osmotica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.8% of Epizyme shares are held by institutional investors. 5.3% of Osmotica Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of Epizyme shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Osmotica Pharmaceuticals beats Epizyme on 9 of the 13 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Osmotica Pharmaceuticals (NASDAQ:OSMT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ORIC Pharmaceuticals and Osmotica Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Osmotica Pharmaceuticals01302.75

ORIC Pharmaceuticals currently has a consensus target price of $43.7143, indicating a potential upside of 111.18%. Osmotica Pharmaceuticals has a consensus target price of $9.25, indicating a potential upside of 203.28%. Given Osmotica Pharmaceuticals' higher possible upside, analysts plainly believe Osmotica Pharmaceuticals is more favorable than ORIC Pharmaceuticals.

Insider and Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.3% of Osmotica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ORIC Pharmaceuticals and Osmotica Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Osmotica Pharmaceuticals-25.26%-13.23%-3.91%

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Osmotica Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Osmotica Pharmaceuticals$240.03 million0.80$-270,900,000.00$0.2512.20

ORIC Pharmaceuticals has higher earnings, but lower revenue than Osmotica Pharmaceuticals.

Summary

ORIC Pharmaceuticals beats Osmotica Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Osmotica Pharmaceuticals and Esperion Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Osmotica Pharmaceuticals01302.75
Esperion Therapeutics24312.30

Osmotica Pharmaceuticals currently has a consensus target price of $9.25, indicating a potential upside of 203.28%. Esperion Therapeutics has a consensus target price of $50.60, indicating a potential upside of 87.06%. Given Osmotica Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Osmotica Pharmaceuticals is more favorable than Esperion Therapeutics.

Profitability

This table compares Osmotica Pharmaceuticals and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Osmotica Pharmaceuticals-25.26%-13.23%-3.91%
Esperion Therapeutics-46.15%-629.88%-41.43%

Risk & Volatility

Osmotica Pharmaceuticals has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Earnings and Valuation

This table compares Osmotica Pharmaceuticals and Esperion Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Osmotica Pharmaceuticals$240.03 million0.80$-270,900,000.00$0.2512.20
Esperion Therapeutics$148.36 million5.18$-97,170,000.00($3.59)-7.66

Esperion Therapeutics has lower revenue, but higher earnings than Osmotica Pharmaceuticals. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Osmotica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Osmotica Pharmaceuticals beats Esperion Therapeutics on 9 of the 12 factors compared between the two stocks.

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Humanigen (NASDAQ:HGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Osmotica Pharmaceuticals and Humanigen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Osmotica Pharmaceuticals01302.75
Humanigen01502.83

Osmotica Pharmaceuticals currently has a consensus target price of $9.25, indicating a potential upside of 203.28%. Humanigen has a consensus target price of $29.8333, indicating a potential upside of 121.97%. Given Osmotica Pharmaceuticals' higher possible upside, equities research analysts clearly believe Osmotica Pharmaceuticals is more favorable than Humanigen.

Insider & Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. 5.3% of Osmotica Pharmaceuticals shares are owned by company insiders. Comparatively, 37.5% of Humanigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Osmotica Pharmaceuticals and Humanigen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Osmotica Pharmaceuticals-25.26%-13.23%-3.91%
HumanigenN/A-302.90%-174.74%

Volatility & Risk

Osmotica Pharmaceuticals has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. Comparatively, Humanigen has a beta of -0.79, meaning that its share price is 179% less volatile than the S&P 500.

Earnings and Valuation

This table compares Osmotica Pharmaceuticals and Humanigen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Osmotica Pharmaceuticals$240.03 million0.80$-270,900,000.00$0.2512.20
HumanigenN/AN/A$-10,290,000.00N/AN/A

Humanigen has lower revenue, but higher earnings than Osmotica Pharmaceuticals.

Summary

Humanigen beats Osmotica Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Earnings and Valuation

This table compares Osmotica Pharmaceuticals and Xenon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Osmotica Pharmaceuticals$240.03 million0.80$-270,900,000.00$0.2512.20
Xenon Pharmaceuticals$6.83 million99.72$-41,600,000.00($1.54)-12.35

Xenon Pharmaceuticals has lower revenue, but higher earnings than Osmotica Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Osmotica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Osmotica Pharmaceuticals and Xenon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Osmotica Pharmaceuticals01302.75
Xenon Pharmaceuticals00503.00

Osmotica Pharmaceuticals currently has a consensus target price of $9.25, indicating a potential upside of 203.28%. Xenon Pharmaceuticals has a consensus target price of $25.25, indicating a potential upside of 32.27%. Given Osmotica Pharmaceuticals' higher possible upside, equities research analysts clearly believe Osmotica Pharmaceuticals is more favorable than Xenon Pharmaceuticals.

Profitability

This table compares Osmotica Pharmaceuticals and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Osmotica Pharmaceuticals-25.26%-13.23%-3.91%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Volatility & Risk

Osmotica Pharmaceuticals has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Insider & Institutional Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.3% of Osmotica Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Osmotica Pharmaceuticals beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Osmotica Pharmaceuticals and Lexicon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Osmotica Pharmaceuticals$240.03 million0.80$-270,900,000.00$0.2512.20
Lexicon Pharmaceuticals$322.07 million2.20$130.13 million$1.353.63

Lexicon Pharmaceuticals has higher revenue and earnings than Osmotica Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Osmotica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Osmotica Pharmaceuticals and Lexicon Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Osmotica Pharmaceuticals01302.75
Lexicon Pharmaceuticals06202.25

Osmotica Pharmaceuticals presently has a consensus target price of $9.25, indicating a potential upside of 203.28%. Lexicon Pharmaceuticals has a consensus target price of $9.40, indicating a potential upside of 95.43%. Given Osmotica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Osmotica Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Profitability

This table compares Osmotica Pharmaceuticals and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Osmotica Pharmaceuticals-25.26%-13.23%-3.91%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Risk and Volatility

Osmotica Pharmaceuticals has a beta of 2.92, meaning that its stock price is 192% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.

Insider and Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. 5.3% of Osmotica Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Osmotica Pharmaceuticals beats Lexicon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.


Osmotica Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Epizyme logo
EPZM
Epizyme
1.8$7.73-0.0%$786.80 million$23.80 million-3.47Analyst Report
News Coverage
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.00-0.2%$772.43 millionN/A0.00Increase in Short Interest
Gap Up
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.49-2.2%$751.39 million$148.36 million-7.14
Humanigen logo
HGEN
Humanigen
1.7$13.67-1.6%$742.87 millionN/A0.00Analyst Report
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.02-4.2%$709.73 million$6.83 million-19.61
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.90-1.2%$698.67 million$322.07 million-4.67Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.28-0.5%$692.81 million$40.89 million-3.20News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.15-0.3%$675.74 million$150,000.00-4.50News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.60-1.2%$671.97 million$19.56 million-19.14
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.59-1.9%$670.57 million$2.22 million-15.24News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.44-1.2%$666.59 million$252 million-2.09
Chimerix logo
CMRX
Chimerix
1.3$7.83-0.8%$665.73 million$12.52 million-13.74
Veru logo
VERU
Veru
1.4$8.99-1.1%$653.68 million$42.59 million-32.11Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.89-3.0%$650.06 million$17.26 million-4.14
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.48-1.3%$648.83 million$13.80 million-13.76Analyst Report
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.86-3.9%$637.44 million$5.09 million-6.43
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.21-1.9%$632.17 millionN/A-2.31Increase in Short Interest
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.01-2.8%$628.85 million$9.64 million-5.21
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.90-6.0%$616.02 millionN/A-4.38Analyst Upgrade
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.60-3.2%$604.18 million$143.01 million-1.07
OrganiGram logo
OGI
OrganiGram
1.6$2.41-7.9%$603.91 million$64.61 million-3.54Analyst Downgrade
Decrease in Short Interest
Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$22.03-1.3%$595.21 million$8 million-8.13
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.52-0.8%$592.94 millionN/A-9.85Analyst Report
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.50-0.9%$591.17 million$59.29 million-23.33Increase in Short Interest
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.90-1.7%$577.60 millionN/A-15.69
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$42.38-0.6%$563.31 million$195.89 million121.09
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$21.17-9.2%$562.00 million$12.69 million-10.18Increase in Short Interest
News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.41-3.1%$551.05 million$26.74 million18.53
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.77-1.1%$547.04 millionN/A-5.17
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.04-0.8%$534.08 million$1.19 million-6.68
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.79-0.2%$521.18 millionN/A-4.60News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.19-2.6%$518.23 millionN/A-8.67
Inventiva logo
IVA
Inventiva
0.0$13.39-0.4%$517.26 millionN/A0.00Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.88-1.0%$513.60 millionN/A-4.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.28-1.7%$510.88 million$25 million-18.89
Provention Bio logo
PRVB
Provention Bio
1.6$7.82-2.9%$510.17 millionN/A-5.25Analyst Report
Increase in Short Interest
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.51-0.1%$509.84 millionN/A-5.39
89bio logo
ETNB
89bio
1.6$25.67-1.4%$505.03 millionN/A-5.08Insider Selling
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.53-2.4%$498.07 millionN/A-8.08
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.20-3.3%$495.20 million$59.22 million41.00
XBiotech logo
XBIT
XBiotech
1.0$16.13-3.9%$493.73 millionN/A1.12News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.75-0.0%$493.31 million$58.12 million-15.99
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.80-2.6%$492.36 million$57.49 million-6.55News Coverage
Gap Up
Akouos logo
AKUS
Akouos
1.6$14.30-0.3%$490.23 millionN/A0.00
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.31-7.4%$483.22 million$40,000.00-1.45Upcoming Earnings
Gap Up
AC Immune logo
ACIU
AC Immune
1.3$6.47-0.6%$468.31 million$111.75 million-7.19Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.10-2.3%$464.67 million$22.27 million-3.97Analyst Revision
Evolus logo
EOLS
Evolus
1.5$10.63-0.1%$464.44 million$34.92 million-5.24Gap Up
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$463.50 million$17.46 million-1.92
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.